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ABSTRACT
Introduction: The use of psychotropic drugs in children and adolescents is widespread but associated
with suboptimal treatment effects. Therapeutic drug monitoring (TDM) can improve safety of psycho-
tropic drugs in children and adolescents but is not routinely performed. A major reason is that the
relationship between drug concentrations and effects is not well known.
Areas covered: This systematic review evaluated studies assessing the relationship between psycho-
tropic drug concentrations and clinical outcomes in children and adolescents, including antipsychotics,
psychostimulants, alpha-agonists, antidepressants, and mood-stabilizers. PRISMA guidelines were used
and a quality assessment of the retrieved studies was performed. Sixty-seven eligible studies involving
24 psychotropic drugs were identified from 9,298 records. The findings were generally heterogeneous
and the majority of all retrieved studies were not of sufficient quality. For 11 psychotropic drugs,
a relationship between drug concentrations and side-effects and/or effectiveness was evidenced in
reasonably reported and executed studies, but these findings were barely replicated.
Expert opinion: In order to better support routine TDM in child- and adolescent psychiatry, future work
must improve in aspects of study design, execution and reporting to demonstrate drug concentration-
effect relationships. The quality criteria proposed in this work can guide future TDM research.
Systematic review protocol and registration
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Psychotropic drugs have been proven effective for the treat-
ment of a wide range of psychiatric disorders in children and
adolescents. As a result, the use of stimulants, antipsychotics,
antidepressants, and mood-stabilizers in youths is widespread
[1–3].
However, the use of psychotropic drugs in youth faces
several challenges. Some side effects of these drugs appear
more prevalent in young patients, like metabolic and endo-
crine abnormalities associated with antipsychotic drug use [4].
This also applies to selective serotonin reuptake inhibitors
(SSRIs), where children seem more vulnerable for restlessness
and vomiting [5]. At the same time, efficacy of some psycho-
tropic drugs may be lower in children than in adults, as
demonstrated for antidepressants [6].
Although the mechanisms behind suboptimal treatment
effects in youths are not fully understood, both pharmacoki-
netic and pharmacodynamic changes during childhood might
contribute. Pharmacokinetic changes that occur during child-
hood [7] may result in over- or underdosing in young patients,
leading to unanticipated failures of randomized controlled
drug trials in child- and adolescent psychiatry [8]. Also phar-
macodynamics might influence suboptimal psychotropic
treatment effects in children and adolescents, as brain devel-
opment and target receptor maturation are suggested to be
related to the failure of many antidepressants in youths [9].
However, age-specific pharmacokinetic and – dynamic aspects
relevant for psychotropic drugs in children and adolescents
are largely unknown.
Therapeutic Drug Monitoring (TDM), which comprises the
quantification of drug concentrations in blood or other
matrices to optimize individual drug dosing [10], incorporates
individual pharmacokinetic and pharmacodynamic processes.
TDM has proven to enhance efficacy and safety of many
psychotropic drugs in adults and has become routine practice
for mood stabilizers like lithium, tricyclic antidepressants like
amitriptyline, and antipsychotics like clozapine in adult psy-
chiatry [10]. TDM is especially indicated for patient popula-
tions with altering pharmacokinetics and pharmacodynamics,
such as elderly, pregnant women, children, and adolescents,
where both efficacy and side-effects might be unpredictable
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[10,11]. As such, TDM may also provide a measure for proac-
tive pharmacovigilance in children and adolescents [12].
However, TDM within child- and adolescent psychiatry is gen-
erally not routinely performed. A major reason is that the relation-
ship between drug concentrations and effects in children and
adolescents is not well known, and age- or developmental spe-
cific therapeutic reference ranges are lacking [13,14]. The objec-
tive of this systematic review is to provide an overview of the
literature investigating the relationship between blood concen-
trations of psychotropic drugs and clinical outcomes in children
and adolescents, including stimulants, antipsychotics, antidepres-
sants and mood-stabilizers and alpha-agonists, to further investi-
gate the rationale for TDM in this population. Based on the
findings, the current position of TDMwithin child- and adolescent
psychiatry and future research directives are discussed.
2. Methods
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) reporting guideline for
systematic reviews [15]. This systematic review is registered
under PROSPERO number CRD42018084159.
2.1. Information sources
Studies were identified by searching electronic databases and
screening reference lists of relevant articles. Three databases
were systematically searched without restriction of language
or publication date (Embase.com, Medline Ovid and Cochrane
CENTRAL). The last search was performed in November 2018.
The search strategy can be found in supplementary table 1.
2.2. Eligibility criteria and study selection
Studies reporting the relationship between psychotropic drug
concentrations and clinical outcomes (i.e. efficacy or safety) in
children or adolescents aged up to 18 years were eligible for
inclusion. The included psychotropic drugs were antipsycho-
tics, psychostimulants, alpha-agonists, antidepressants, and
mood-stabilizers including anti-epileptics used for psychiatric
indications. The eligibility criteria are presented in Table 1.
Title abstract and full-text screen was independently per-
formed by two reviewers (SK and DV); disagreements were
resolved by consensus. References of identified studies were
checked for relevant articles. Also, previous reviews and the
international consensus guideline about TDM in psychiatry
were checked for relevant studies [10,13,14].
2.3. Data collection process
One reviewer (SK) extracted the following data from included
studies in a data extraction form: (1) characteristics of study
participants (including sex, age, and diagnoses), (2) study
design (including duration and dosing strategy), (3) outcome
measures, (4) blood sample collection (sampling time, relation
to steady state) and (5) the results as presented in the study.
A second reviewer (KP) checked doubtful items identified by
the first reviewer. Disagreements were resolved by discussion
between reviewers.
2.4. Quality assessment of therapeutic drug monitoring
To ascertain the internal validity of the selected studies, one
reviewer (SK) performed a quality assessment of the therapeu-
tic drug monitoring component of the selected studies.
A second reviewer (KP) checked doubtful quality criteria that
were identified by the first reviewer during the quality assess-
ment. Disagreements were resolved by discussion between
reviewers.
Currently available quality assessment tools do not specifi-
cally address drug concentration-effect studies [16], thus criteria
for quality assessment were adapted from a previously pub-
lished meta-analysis of Ulrich et al. concerning the concentra-
tion-therapeutic effect relationship of haloperidol in adults [17].
As the current systematic review covers different types of psy-
chotropic drugs with a broad range of indications, not all criteria
of the total score as used by Ulrich et al. were applicable. We
therefore used only the hard items of the total score. These
items are indicated ‘sufficient’ or ‘insufficient’ and presented in
Table 2. Studies that did not report or did not realize an item
were rated insufficient. Premedication was registered as study
characteristic and not scored. Furthermore, ‘completely insuffi-
cient description of study design’ was not included as score
Article highlights
● The concentration-effect relationships of psychotropic drugs in chil-
dren and adolescents are largely unknown, which hampers the
routine application of Therapeutic Drug Monitoring (TDM) in this
population.
● Our systematic literature search favors a concentration-effect relation-
ship for 11 psychotropic drugs in children and adolescents with
different indications, but evidence is sparse and therapeutic reference
ranges are generally not evaluated or reported.
● Most retrieved studies did not accurately report or execute key
aspects of TDM.
● Even when therapeutic reference ranges are not well established,
TDM can improve psychopharmacotherpay when non-compliance,
drug–drug interactions, or pharmacogenetic polymorphisms are sus-
pected in children and adolescents.
This box summarizes key points contained in the article.
Table 1. In- and exclusion criteria for selection of relevant articles.
Inclusion criteria Exclusion criteria
● The study concerns antipsychotics,
psychostimulants, antidepressants
or mood-stabilizers, alpha-agonists
● No analysis on relationship
between drug levels and clinically
relevant outcome measures is
reported
● Study is performed in children or
adolescents aged up to 18 years
● Drug under study is used for non-
psychiatric indications (f.e. epilepsy
or enuresis)
● Drug plasma levels are measured
and reported
● Maternal use during pregnancy or
lactation
● Direct clinical outcome measures
are reported, i.e. safety or efficacya
● Non-human subjects
● Studies focusing on toxicology/
overdoses
● Case reports
● Conference papers and abstracts
● Postmortem studies
abiomarkers are not regarded a direct clinical outcome measure.
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item, as individual items were already rated insufficient when
the information could not be found.
2.4.1. Analytical method for the assay of drug
concentration in serum or plasma
The analytical assay for drug quantification should be selective,
able to discriminate the measured drug from other similar drugs
and metabolites, and sensitive, accurately quantifying drug con-
centration [10]. Accurate analytical methods have become avail-
able relatively recently [18]. Examples of selective and sensitive
methods include chromatographic methods, including High-
Performance Liquid Chromatography (HPLC) and Liquid
Chromatography-Mass Spectrometry (LC-MS). Older analytical
methods like (radio) immunoassay often present high variability
in drug quantification. Analytical methods for drug quantification
must be validated to demonstrate reliability and reproducibility.
The quality assessment of the analytical method was checked
per study by a laboratory-based hospital pharmacist (BK).
2.4.2. Blood sample collection
Steady state is achieved when a drug is given in a constant
dose and schedule for at least 4–6 half-lives [10]. During
steady state, overall bioavailability is in equilibrium with elim-
ination, such that the drug concentration reflects the dosage
given. Sampling should therefore be performed during steady
state of the drug and its metabolites. An exception is when
population pharmacokinetic-pharmacodynamic modeling is
performed, which can correct for non-steady state concentra-
tions. Furthermore, the concentration of a drug rises quickly
after drug intake and declines afterward as a function of time.
An accurate assessment of the time interval between sam-
pling relative to the drug intake is crucial for correct inter-
pretation of the drug concentration. In clinical practice,
sampling of the trough concentration is often the standard
procedure. The trough concentration is the concentration at
the end of a dosing interval, taken immediately before the
subsequent dose. The concentration-time curve in the final
period of the dose interval is relatively flat, and therefore the
exact sampling time is less critical. For normal release methyl-
phenidate formulations, steady state sampling is not relevant
due to its short half-life, and thus this item was not weighed in
scoring.
2.4.3. Patient selection
A representative sample is important for the generalizability of
results (external validity). If a heterogeneous patient group is
selected, and there is concern that different relationships exist
between drug plasma concentrations and (side-) effects, sub-
group analysis should be performed, bearing in mind that ade-
quate power is achieved. Furthermore, psychiatric classifications
within the sample and the associated classification system should
be reported, as concentration reference ranges are disorder-
specific.
2.4.4. Measurement of illness severity and registration of
therapeutic improvement or worsening
For the analysis of the relationship between drug concentra-
tions and effect, it is important to assess the effect that is likely
to be attributable to the drug. Therefore, a baseline assess-
ment of the severity of the outcome measure, prior to drug
treatment, is essential. The change from baseline should be
used for analyses rather than a point measurement during
treatment. Preferably a validated rating scale should be used
to determine outcome measures. Lastly, a sufficient time to
rate effect should be considered. For example with antipsy-
chotics, a delay of at least 1 week after start of treatment is
expected to observe a clinical effect [17].
2.4.5. Comedication
Comedication can influence the effect of drug trough phar-
macokinetic and pharmacodynamic interactions. In particular,
pharmacodynamic interactions might confound the observed
clinical effects. Co-medication should be taken into account
and corrected for when necessary, where possible trough
strategies such as stratification or multivariate methods.
Table 2. Criteria for quality assessment of the selected studies.
Quality criteria Sufficient score Comments
1. Analytical method for the assay of drug
concentration in serum or plasma
– Validated analytical method
2. Blood sample collection
3. Patient selection
4. Measurement of illness severity and
registration of therapeutic improvement or
worsening
– Steady state plasma or serum concentrations
– Sampling time and drug intake described
– Representative sample for study outcome
– Psychiatric classifications and associated classification system
are reported
– Adequate quantification of outcome measure (rating with
a structured scale)
– A baseline assessment of the outcome measure is provided
– Adequate calculation of change in outcome measure
– Sufficient time to rate effect
With a heterogeneous sample, a sub analysis
per relevant category should be provided
Retrospectively scored change is rated
insufficient
5. Comedication – No drug that influences pharmacokinetics or
pharmacodynamics of the drug under study is taken
simultaneously, or:
– A sub analysis/correction is provided
6. Number of patients – At least 10 patients are included and used for analysis
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2.4.6. Number of patients
Power calculations are challenging in observational studies,
and in the setting of observational studies in TDM. Ulrich
et al. [17] suggest a minimum of 10 patients, which was
rated a sufficient number within our quality assessment.
3. Results
3.1. Study selection
Figure 1 shows the process by which articles were identified.
Screening of title and abstract identified 311 primary studies.
Full-text was not available for 43 of these.
Sixty-seven studies were included after full-text screen,
representing 24 psychotropic drugs: two stimulants, one
alpha-agonist, six SSRI’s, five tricyclic antidepressants, one
other antidepressant, seven antipsychotics, and two mood
stabilizers.
Of the selected studies, 35.8% evaluated efficacy measures,
32.8% evaluated side-effect measures and 31.3% evaluated
both. A substantial proportion of studies was performed
prior to 1995 (n = 23, 34.3%). Most studies were performed
in the United States (n = 42, 62.7%), and 25.3% of studies were
performed in Europe.
3.2. Quality assessment
Twenty-one studies met all six quality criteria (31.3%), while 47
studies did not meet quality criteria in full (one study
described two trials, and fulfilled all criteria for one trial [19]).
Five criteria were met in 25 studies (37.3%).
The most frequently missed criterion was comedication and
blood sample collection. Comedication was rated as insufficient
in 25 studies (37.3%); it was unreported in 9 studies (13.4%)
and was not addressed in analyses in 16 studies (22.4%). Blood
sample collection was insufficient in 24 studies (35.8%), where
either sampling in steady state was not performed, or time
point of sampling relative to the drug intake was not
described. Measurement of illness severity and registration of
therapeutic improvement or worsening was rated as insufficient
in 20 studies (29.9%), principally as baseline measurement was
not performed. The analytical method was scored insufficient
in 10 studies (14.9%), the method was judged nonselective or
nonsensitive in 3 studies, and the analytical method was not
reported in 7 studies.
The characteristics, results, and quality assessment of the
studies are presented in Table 3.
The studies meeting all quality criteria involved 15 psycho-
tropic drugs. A concentration–efficacy relationship was found
for six drugs (citalopram [51], fluoxetine [51], nortriptyline [52],
buproprion [53], quetiapine [54], lithium [55]), a concentration-
Records identified through database 
searching Embase.com, Medline Ovid, 
Cochrane CENTRAL 
(n = 9298 )
Additional records identified 
through cross reference 
checking 
(n=4) 
Records after duplicates removed 
(n = 7722) 
Records screened 
(n =  7722) 
Records excluded 
(n =7411) 
Full-text articles assessed for 
eligibility 
(n =311) 
Full-text articles excluded: total 248 
- Study not performed in children or 
adolescents: 103 
- Relationship between drug levels and 
clinically relevant outcome measures  not 
assessed: 86 
- Medication not taken for psychiatric 
indication (epilepsy/migraine/apnea): 13 
- Toxicology/overdoses: 1 
- Case report: 2 
- No full text available: 43 
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side-effects relationship was found for three (venlafaxine [51],
desipramine [56], ziprasidone [57]), and a relationship with
both efficacy and side-effects for two (methylphenidate
[19,58–60], imipramine [61–63]). The indications for use of
these drugs included major depression, conduct disorder,
bipolar disorder, attention-deficit disorder with or without
hyperactivity and Tourette syndrome or chronic tic disorder
(Table 3). In seven of the studies meeting all quality criteria,
therapeutic reference ranges or concentrations for optimal
treatment were reported [52–55,60–62].
The 47 studies that did not meet all quality criteria involved
20 psychotropic drugs, for which concentration-effect relation-
ships were reported for 13. These concerned eight additional
drugs compared to the studies judged high-quality studies:
one with a concentration–efficacy relationship (atomoxetine
[64]), six with a concentration-side-effect relationship (fluvox-
amine [65], sertraline [66], clomipramine [67], haloperidol [68],
olanzapine [69,70], risperidone [70–74]), and one with both
(clozapine [75–77]). In nine of the studies with lower quality,
suggested therapeutic reference ranges or optimal concentra-
tions were reported [67,68,77–83].
For 5 of the 24 psychotropic drugs that were retrieved with
our search, no relationship between concentration and clinical
outcomes was found in either high-quality studies or lower-
quality studies (dexamphetamine, paroxetine, imipramine, lox-
apine, valproic acid).
Overall, findings were highly heterogeneous. Most studies
were not primarily designed to assess the relationship
between drug concentrations and effects. Furthermore, most
of the studies were not replicated and for most drugs and
outcomes, only one study was available.
4. Conclusions
This systematic review presents published evidence for the
relationship between drug concentration and clinical out-
comes of psychotropic drugs in children and adolescents. We
found a minority of therapeutic drug monitoring studies were
reasonably reported and executed. Among these, concentra-
tion-effect relationships were evidenced for methylphenidate,
citalopram, fluoxetine, venlafaxine, desipramine, imipramine,
nortriptyline, bupropion, quetiapine, ziprasidone, and lithium,
for various indications in children and adolescents. However,
findings were often heterogeneous, barely replicated and
therapeutic reference ranges were not often provided.
Moreover, interpretation of data from retrieved studies was
primarily complicated by inappropriately conducted or inade-
quately reported sampling.
5. Expert opinion
5.1. Considering the relevance of a drug
concentration-effect relationship in the clinical context
Although for a wide range of psychotropic drugs some evi-
dence was found for a concentration-effect relationship, its
relevance in clinical practice depends on several drug-related
and clinical factors [84], including the time-course of the
observed effects.
For instance, the relationship between systemic methylphe-
nidate concentrations and efficacy in children and adolescents
with Attention-Deficit Hyperactivity Disorder was frequently
reported, but might be of questionable relevance. Among
160 children and adolescents across three reasonably reported
and executed trials, a higher methylphenidate concentration
was associated with improved performance, though different
instruments were used across the studies [58–60]. Most stu-
dies judged of lower quality reported similar findings, with
one exception [85]; however, the length of the follow-up
period was unclear in this work, thus the relationship might
have been underestimated. These findings suggest that this
stimulant might be a candidate for TDM in children and
adolescents, although routine application should be carefully
considered [84]. As improvement in attention is readily asses-
sable by parents and teachers [86], it is questionable that
concentration measurement would further inform clinical
decision-making.
TDM may be more informative for psychotropic drugs with
delayed therapeutic or side-effects, such as antidepressants or
antipsychotic drugs. TDM would ideally provide important
information on adequacy of therapy in an early phase, thereby
preventing sub-therapeutic treatment and long-term side-
effects. Given growing concerns about antipsychotic-induced
metabolic abnormalities in children and adolescents [87],
these drugs could be an important target for TDM.
Unfortunately, no relationship was found in two studies eval-
uating the relationship between antipsychotic concentrations
and metabolic outcomes such as weight, glucose, and fatty
acids in children and adolescents [88,89]. However, these stu-
dies did not perform baseline measurements and the relation-
ship may be underestimated. Others report associations
between higher dose and weight gain [90,91], thus
a relationship with systemic concentrations is suspected.
Another aspect that should be considered when assessing
the relevance of a drug concentration-effect relationship, is
the margin between effective and toxic drug concentrations. If
this margin is very narrow, as for example for lithium, it is
important to closely monitor drug concentrations to prevent
intoxications. For this reason, routine TDM is recommended
for lithium in children and adolescents [92]. At the same time,
for drugs with a very wide window, as generally applies to
SSRIs, TDM is expected to be less useful in routine care, but
may be useful to objectify nonadherence. Furthermore, the
drug concentrations after a given dosage should be difficult to
predict. This is referred to as a high inter-individual pharmaco-
kinetic variation and means that drug concentrations differ
largely between patients after administration of equal
dosages. Another aspect that should be considered for the
clinical application of TDM, is that a rapid and reliable method
for analysis of the drug should be available. Lastly, before TDM
is routinely applied, it should be demonstrated that TDM
improves patient outcomes and is cost-effective in clinical
practice.
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5.2. Research recommendations to support TDM in child-
and adolescent psychiatry
A proven drug concentration-effect relationship is the first
step to provide a rationale for TDM, but this was only sparsely
evidenced for most psychotropic drugs in children and ado-
lescents. In order to better demonstrate drug concentration-
effect relationships in this field, future work must improve in
aspects of study design, execution, and reporting. Many stu-
dies failed to perform standardized sampling, including sam-
pling with respect to steady state and administration time.
Therefore, there is a need for an accepted tool for the apprai-
sal of drug concentration-effect studies [10,16]. The assess-
ment criteria proposed by this report could serve as
a starting point, hopefully reducing the heterogeneity
observed to date, and permitting meta-analyses.
Besides the need for more adequate sampling protocols,
also study designs should be considered for their feasibility
and appropriateness to demonstrate a drug concentration-
effect relationship. Pharmacokinetic and – dynamic research
in children with psychiatric morbidities is challenging and is
liable to ethical constraints. As such, observational study
designs may provide initial estimates toward defining refer-
ence ranges for this patient group. However, results should be
interpreted in the light of their limitations. Flexible dosing
schemes might lead to an underestimation of the concentra-
tion-effect relationship due to the placebo effect that is com-
mon for psychotropic drugs. Lower dosages, and thus lower
drug concentrations, are likely used in placebo-responders,
weakening association estimates [93]. Furthermore, observa-
tional studies often permit dosage changes and comedication,
thereby altering concentrations of the index drug and compli-
cating analyses with respect to outcomes. In particular within
child- and adolescent psychiatry, psychotropic comedication is
very common and should be considered [94]. Also, non-
pharmacological interventions such as behavioral interven-
tions are commonly part of multimodal treatment, possibly
influencing therapeutic outcomes. Results of observational
work can nevertheless be very valuable, especially when
aspects of therapeutic drug monitoring are well-reported
and well executed. It may be argued that if dose-effect rela-
tionships are apparent in the setting of observational study
designs, the effect would be more pronounced in
a randomized controlled trial that involves titration to concen-
trations associated with efficacy.
However, before TDM is routinely applied in clinical practice,
preferably its effect on patient outcomes is evaluated. Ideally, to
demonstrate that TDM can improve clinical outcomes, rando-
mized controlled trials would be used to evaluate TDM as an
intervention, comparing clinician directed dosing with dose
adjustment based on drug monitoring, or comparing different
target concentrations [10]. Relevant outcomes would include
response, side-effects and cost-effectiveness. An excellent
example of such a trial investigating effects and side-effects is
the randomization to one of the three target concentrations for
clozapine in adults [95]; however, no such RCTs have been
performed for psychotropic drugs in children and adolescents.
This is partly due to difficulties in performing such trials within
child- and adolescent psychiatry [96]. However, in general, such
RCTs are very rare in the field of TDM and are therefore not
always required before its implementation in clinical practice.
5.3. TDM in adult psychiatry
Within adult psychiatry, TDM is generally recommended for
lithium,most tricyclic antidepressants, and clozapine. For lithium,
TDM is even considered mandatory given its small therapeutic
window and relatively high risk for altering concentrations, due
to the fully renal excretion and several known drug–drug inter-
actions. The Consensus Guidelines for Therapeutic Drug
Monitoring in Neuropsychopharmacology also highly recom-
mends TDM for several other psychotropic drugs in adults,
including olanzapine, haloperidol, carbamazepine, and valpro-
ate. This guideline provides therapeutic reference ranges in
adults, although these ranges are regularly based on observed
values in the population rather than based on RCTs. The cost-
effectiveness of TDM in adult psychiatry has only poorly been
investigated, and RCTs investigating TDM as an intervention
have rarely been done. Nevertheless, TDM is, based on consider-
ably better documented concentration-effect relationships than
in children and adolescents, considered a helpful and well-
accepted tool to improve pharmacopsychiatry in adults.
5.4. Current position of TDM within child- and
adolescent psychiatry
Almost no studies reported therapeutic reference ranges for
psychotropic drugs in children and adolescents. Unfortunately,
ranges cannot be simply extrapolated from adults, as both
pharmacokinetic and pharmacodynamic processes differ con-
siderably. This is the result of developmental changes in body
composition, target receptor maturation, and organ ripening
[7], generally leading to lower psychotropic drug concentra-
tions in children and adolescents than recommended thera-
peutic reference ranges in adults [12]. Also, psychotropic
drugs may be used for other indications in children and
adolescents than in adults, and in other dosages, such as
antipsychotic drugs (behavioral problems versus psychosis).
The absence of established reference ranges prevents rou-
tine application of TDM on a population level. An exception
applies to lithium, for which routine TDM is recommended
based on a known narrow therapeutic range in adults, which
is also applied in children and adolescents [92]. Within our
systematic review, one well documented and executed study
found a drug concentration-effect relationship in pediatric
patients with bipolar I disorder [55], but studies that system-
atically investigate the added value and optimal concentra-
tions of lithium in clinical practice are lacking. For other
psychotropic drugs, despite the unavailability of clear-cut con-
centration effect-relationships, TDM can be of added value on
an individual level when noncompliance is suspected or,
drug–drug interactions or pharmacogenetic polymorphisms,
for example, in cytochrome 2D6, are foreseen in children and
adolescents using psychotropic drugs. A drug concentration
measurement can identify unexpected concentrations, as for
many antipsychotic drugs expected concentrations based on
a given dosage in steady state are known [97]. These are called
pharmacokinetic reference ranges and can optimize
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antipsychotic pharmacotherapy by guiding dose- or comedi-
cation adjustments. In this way, TDM can prevent over- or
underdosing, and improve psychotropic pharmacological
treatment in children and adolescents. As long-term safety
data of psychotropic drugs in this population are generally
lacking and these drugs are frequently prescribed off-label,
TDM can provide an important tool to improve psychophar-
macotherapy in children and adolescents.
6. Limitations
The results of this systematic review should be interpreted in
the light of its limitations. Firstly, among quality assessment
criteria, unreported elements were judged insufficient.
However, older work might have reported data on metho-
dological aspects more concisely, thus might have been
assessed too strictly. As such, five studies were rated insuffi-
cient for the item comedication. Secondly, a substantial num-
ber of articles were not available full text, primarily reflecting
older work. However, based on title and abstract screen,
these are not expected to have influenced our conclusions.
Thirdly, the older publications also concerned drugs that are
currently not widely used in children and adolescents any-
more, such as tricyclic antidepressants. Fourthly, publication
bias is a possibility that due to heterogeneity we were
unable to evaluate, and this may have bias our findings
toward positive results. Lastly, the scope of the current
review was very broad and aimed at providing an overview
of the current literature, which limits a more profound dis-
cussion of the individual drugs.
Acknowledgments
The authors acknowledge the contribution of W Bramer and S Gunput of
Erasmus MC in performing the search strategy.
Author contributions
All authors are accountable for all aspects of the work and approved the
final version to be published. Conception and design: SMK, KME, MG, BD
and BCPK. Analysis and interpretation of the data: SMK, DV, JS and KMP.
Drafting of the paper: SMK. Revising the paper critically for intellectual
content: JS, KME, MG, GCD, MHJH, TvG, BD and BCPK.
Funding
SM Kloosterboer, B Dierckx and BC Koch received grant research support
from The Netherlands Organization for Health Research and Development
(ZonMW), number [836041011]. KM Egberts received grant research sup-
port from the Federal Institute for Drugs and Medical Devices, Bonn
[BfArM- reference number: V-15322/68605/2013-2018]. MHJ Hillegers
received grant research support from The Netherlands Organization for
Health Research and Development (ZonMW), grant 60-63600-98-021.
Declaration of interest
T van Gelder has received lecture fees and study grants from Chiesi and
Astellas, in addition to consulting fees from Roche Diagnostics, Vitaeris,
Astellas, Aurinia Pharma, and Novartis. The authors have no other relevant
affiliations or financial involvement with any organization or entity with
a financial interest in or financial conflict with the subject matter or
materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other
relationships to disclose.
ORCID
Sanne M. Kloosterboer http://orcid.org/0000-0003-2573-4636
Karin M. Egberts http://orcid.org/0000-0002-0270-0954
Manon H. J. Hillegers http://orcid.org/0000-0003-4877-282X
References
Papers of special note have been highlighted as either of interest (•) or of
considerable interest (••) to readers.
1. Sultan RS, Correll CU, Schoenbaum M, et al. National patterns of
commonly prescribed psychotropic medications to young people.
J Child Adolesc Psychopharmacol. 2018 Apr;28(3):158–165. .
2. Kloosterboer SM, Schuiling-Veninga CCM, Bos JHJ, et al.
Antipsychotics in Dutch youth: prevalence, dosages, and duration
of use from 2005 to 2015. J Child Adolesc Psychopharmacol. 2018
Mar 13;28: 173-179.
3. Bachmann CJ, Aagaard L, Burcu M, et al. Trends and patterns of
antidepressant use in children and adolescents from five western
countries, 2005–2012. Eur Neuropsychopharmacol. 2016 Mar;26
(3):411–419.
4. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of
psychotropic medications in children and adolescents. J Am Acad
Child Adolesc Psychiatry. 2006 Jul;45(7):771–791.
5. Safer DJ, Zito JM. Treatment-emergent adverse events from selec-
tive serotonin reuptake inhibitors by age group: children versus
adolescents. J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16
(1–2):159–169.
6. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and
tolerability of antidepressants for major depressive disorder in
children and adolescents: a network meta-analysis. Lancet. 2016
Aug 27;388(10047):881–890.
7. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental
pharmacology–drug disposition, action, and therapy in infants and
children. N Engl J Med. 2003 Sep 18;349(12):1157–1167.
8. Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of
pharmacokinetic studies in designing efficacy trials in juvenile
major depression. J Child Adolesc Psychopharmacol. 2006 Feb-
Apr;16(1–2):131–145.
9. Hazell P, O’Connell D, Heathcote D, et al. Efficacy of tricyclic drugs
in treating child and adolescent depression: a meta-analysis. Bmj.
1995 Apr 8;310(6984):897–901.
10. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines
for therapeutic drug monitoring in neuropsychopharmacology:
update 2017. Pharmacopsychiatry. 2018 Jan;51(1/2):9–62. .
• An overview of recommendations and background of TDM in
adult psychiatry, provided by the AGNP consensus group.
11. Egberts KM, Mehler-Wex C, Gerlach M. Therapeutic drug monitor-
ing in child and adolescent psychiatry. Pharmacopsychiatry. 2011
Sep;44(6):249–253.
•• Provides the rationale for TDM in child and adolescents psychia-
try, and explains why this is important.
12. Gerlach M, Egberts K, Dang SY, et al. Therapeutic drug monitoring
as a measure of proactive pharmacovigilance in child and adoles-
cent psychiatry. Expert Opin Drug Saf. 2016 Nov;15(11):1477–1482.
•• This article explains why TDM is important to improve pharma-
cotherapy in child and adolescent psychiatry.
13. Pichini S, Papaseit E, Joya X, et al. Pharmacokinetics and therapeu-
tic drug monitoring of psychotropic drugs in pediatrics. Ther Drug
Monit. 2009 Jun;31(3):283–318.
14. Whitney Z, Boyda HN, Procyshyn RM, et al. Therapeutic drug levels
of second generation antipsychotics in youth: a systematic review.
J Child Adolesc Psychopharmacol. 2015 Apr;25(3):234–245.
14 S. M. KLOOSTERBOER ET AL.
15. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. PLoS
Med. 2009 Jul 21;6(7):e1000097.
16. Cooney L, Loke YK, Golder S, et al. Overview of systematic reviews
of therapeutic ranges: methodologies and recommendations for
practice. BMC Med Res Methodol. 2017 Jun 2;17(1):84.
17. Ulrich S, Wurthmann C, Brosz M, et al. The relationship between
serum concentration and therapeutic effect of haloperidol in
patients with acute schizophrenia. Clin Pharmacokinet. 1998
Mar;34(3):227–263.
18. Hiemke C. Clinical utility of drug measurement and pharmacoki-
netics: therapeutic drug monitoring in psychiatry. Eur J Clin
Pharmacol. 2008 Feb;64(2):159–166.
19. Shaywitz SE, Hunt RD, Jatlow P. Psychopharmacology of attention
deficit disorder: pharmacokinetic, neuroendocrine, and behavioral
measures following acute and chronic treatment with
methylphenidate. PEDIATRICS. 1982;69(6):688–694.
20. Hazell P, Becker K, Nikkanen EA, et al. Relationship between atomox-
etine plasma concentration, treatment response and tolerability in
attention-deficit/hyperactivity disorder and comorbid oppositional
defiant disorder. Atten Defic Hyperact Disord. 2009;1(2):201–210.
21. Brown GL, Hunt RD, Ebert MH. Plasma levels of d-amphetamine in
hyperactive children. Serial behavior and motor responses.
Psychopharmacology (Berl). 1979;62(2):133–140.
22. Gualtieri CT, Kanoy R, Hawk B. Growth hormone and prolactin
secretion in adults and hyperactive children: relation to methyl-
phenidate serum levels. Psychoneuroendocrinology. 1981;6
(4):331–339.
23. Jonkman LM, Verbaten MN, De Boer D, et al. Differences in plasma
concentrations of the D- and L-threo methylphenidate enantiomers
in responding and non-responding children with attention-deficit
hyperactivity disorder. Psychiatry Res. 1998;78(1–2):115–118.
24. Kimko H, Gibiansky E, Gibiansky L, et al. Population pharmacody-
namic modeling of various extended-release formulations of
methylphenidate in children with attention deficit hyperactivity
disorder via meta-analysis. J Pharmacokinet Pharmacodyn.
2012;39(2):161–176.
25. Sebrechts MM, Shaywitz SE, Shaywitz BA. Components of attention,
methylphenidate dosage, and blood levels in children with atten-
tion deficit disorder. Pediatrics. 1986;77(2):222–228.
26. Srinivas NR, Hubbard JW, Quinn D, et al. Enantioselective pharma-
cokinetics and pharmacodynamics of dl-threo-methylphenidate in
children with attention deficit hyperactivity disorder. Clin
Pharmacol Ther. 1992;52(5):561–568.
27. Winsberg BG, Kupietz SS, Sverd J. Methylphenidate oral dose
plasma concentrations and behavioral response in children.
Psychopharmacology (Berl). 1982;76(4):329–332.
28. Blázquez A, Mas S, Plana MT, et al. Plasma fluoxetine concentra-
tions and clinical improvement in an adolescent sample diagnosed
with major depressive disorder, obsessive-compulsive disorder, or
generalized anxiety disorder. J Clin Psychopharmacol. 2014;34
(3):318–326.
29. Koelch M, Pfalzer AK, Kliegl K, et al. Therapeutic drug monitoring of
children and adolescents treated with fluoxetine.
Pharmacopsychiatry. 2012;45(2):72–76.
30. Alderman J, Wolkow R, Chung M, et al. Sertraline treatment of
children and adolescents with obsessive- compulsive disorder or
depression: pharmacokinetics, tolerability, and efficacy. J Am Acad
Child Adolesc Psychiatry. 1998;37(4):386–394.
31. Alderman J, Wolkow R, Fogel IM. Drug concentration monitoring
with tolerability and efficacy assessments during open-label,
long-term sertraline treatment of children and adolescents.
J Child Adolesc Psychopharmacol. 2006;16(1–2):117–129.
32. Moen Olig R, Dennis Staton R, Beatty WW. Antidepressant treat-
ment of children: clinical relapse is unrelated to tricyclic plasma
concentrations. Percept Mot Skills. 1985;60(3):879–889.
33. Flament MF, Rapoport JL, Berg CJ. Clomipramine treatment of
childhood obsessive-compulsive disorder. A double-blind con-
trolled study. Arch Gen Psychiatry. 1985;42(10):977–983.
34. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind pla-
cebo controlled study of desipramine in the treatment of ADD: II.
Serum drug levels and cardiovascular findings. J Am Acad Child
Adolesc Psychiatry. 1989;28(6):903–911.
35. Spencer T, Biederman J, Coffey B, et al. A double-blind comparison
of desipramine and placebo in children and adolescents with
chronic tic disorder and comorbid attention-deficit/hyperactivity
disorder. Arch Gen Psychiatry. 2002;59(7):649–656.
36. Geller B, Farooki ZQ, Cooper TB. Serial ECG measurements at con-
trolled plasma levels of nortriptyline in depressed children. Am
J Psychiatry. 1985;142(9):1095–1097.
37. Birmaher B, Waterman GS, Ryan ND, et al. Randomized, controlled
trial of amitriptyline versus placebo for adolescents with ‘treat-
ment-resistant’ major depression. J Am Acad Child Adolesc
Psychiatry. 1998;37(5):527–535.
38. Biederman J, Baldessarini RJ, Goldblatt A, et al. A naturalistic study
of 24-hour electrocardiographic recordings and echocardiographic
findings in children and adolescents treated with desipramine.
J Am Acad Child Adolesc Psychiatry. 1993;32(4):805–813.
39. Wilens TE, Biederman J, Baldessarini RJ, et al. Electrocardiographic
effects of desipramine and 2-hydroxydesipramine in children, ado-
lescents, and adults treated with desipramine. J Am Acad Child
Adolesc Psychiatry. 1993;32(4):798–804.
40. Ryan ND, Puig-Antich J, Cooper T. Imipramine in adolescent major
depression: plasma level and clinical response. Acta Psychiatr
Scand. 1986;73(3):275–288.
41. Sallee FR, Miceli JJ, Tensfeldt T, et al. Single-dose pharmacokinetics
and safety of ziprasidone in children and adolescents. J Am Acad
Child Adolesc Psychiatry. 2006;45(6):720–728.
42. Slooff VD, Van Den Dungen DK, Van Beusekom BS, et al. Monitoring
haloperidol plasma concentration and associated adverse events in
critically ill children with delirium: first results of a clinical protocol
aimed to monitor efficacy and safety [Article]. Pediatr Crit Care
Med. 2018;19(2):e112–e119.
43. Selim S, Riesenberg R, Cassella J, et al. Pharmacokinetics and safety
of single-dose inhaled loxapine in children and adolescents.
44. Albantakis L, Egberts K, Burger R, et al. Relationship between daily
dose, serum concentration, and clinical response to quetiapine in
children and adolescents with psychotic and mood disorders.
Pharmacopsychiatry. 2017;50(6):248–255.
45. Gagliano A, Germano E, Pustorino G, et al. Risperidone treatment of
children with autistic disorder: effectiveness, tolerability, and phar-
macokinetic implications. J Child Adolesc Psychopharmacol. 2004
Spring;14(1):39–47.
46. Correll CU, Lops JD, Figen V, et al. QT interval duration and disper-
sion in children and adolescents treated with ziprasidone. J Clin
Psychiatry. 2011;72(6):854–860.
47. Amitai M, Zivony A, Kronenberg S, et al. Short-term effects of
lithium on white blood cell counts and on levels of serum
thyroid-stimulating hormone and creatinine in adolescent inpati-
ents: A retrospective naturalistic study. J Child Adolesc
Psychopharmacol. 2014;24(9):494–500.
48. Patel NC, DelBello MP, Bryan HS, et al. Open-label lithium for the
treatment of adolescents with bipolar depression. J Am Acad Child
Adolesc Psychiatry. 2006;45(3):289–297.
49. Siegel M, Beresford CA, Bunker M, et al. Preliminary investigation of
lithium for mood disorder symptoms in children and adolescents
with autism spectrum disorder. J Child Adolesc Psychopharmacol.
2014;24(7):399–402.
50. Amitai M, Sachs E, Zivony A, et al. Effects of long-term valproic acid
treatment on hematological and biochemical parameters in ado-
lescent psychiatric inpatients: A retrospective naturalistic study.
Int Clin Psychopharmacol. 2015;30(5):241–248.
51. Sakolsky DJ, Perel JM, Emslie GJ, et al. Antidepressant exposure as
a predictor of clinical outcomes in the Treatment of Resistant
Depression in Adolescents (TORDIA) study. J Clin
Psychopharmacol. 2011 Feb;31(1):92–97.
52. Geller B, Cooper TB, Chestnut EC. Preliminary data on the relation-
ship between nortriptyline plasma level and response in depressed
children. Am J Psychiatry. 1986;143(10):1283–1286.
EXPERT OPINION ON DRUG SAFETY 15
53. Burleson Daviss W, Perel JM, Brent DA, et al. Acute antidepressant
response and plasma levels of bupropion and metabolites in a
pediatric-aged sample: an exploratory study. Ther Drug Monit.
2006;28(2):190–198.
54. Findling RL, Reed MD, O’Riordan MA, et al. Effectiveness, safety, and
pharmacokinetics of quetiapine in aggressive children with conduct
disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):792–800.
55. Landersdorfer CB, Findling RL, Frazier JA, et al. Lithium in paediatric
patients with bipolar disorder: implications for selection of dosage
regimens via population pharmacokinetics/pharmacodynamics.
Clin Pharmacokinet. 2017;56(1):77–90.
56. Donnelly M, Zametkin AJ, Rapoport JL. Treatment of childhood
hyperactivity with desipramine: plasma drug concentration, cardi-
ovascular effects, plasma and urinary catecholamine levels, and
clinical response. Clin Pharmacol Ther. 1986;39(1):72–81.
57. Sallee FR, Gilbert DL, Vinks AA, et al. Pharmacodynamics of zipra-
sidone in children and adolescents: impact on dopamine
transmission. J Am Acad Child Adolesc Psychiatry. 2003;42
(8):902–907.
58. Quinn D, Wigal S, Swanson J, et al. Comparative pharmacody-
namics and plasma concentrations of d-threo-methylphenidate
hydrochloride after single doses of d-threo- methylphenidate
hydrochloride and d,l-threo-methylphenidate hydrochloride in a
double-blind, placebo-controlled, crossover laboratory school
study in children with attention-deficit/hyperactivity disorder.
J Am Acad Child Adolesc Psychiatry. 2004;43(11):1422–1429.
59. Teicher MH, Polcari A, Foley M, et al. Methylphenidate blood levels
and therapeutic response in children with attention-deficit hyper-
activity disorder I. Effects of different dosing regimens. J Child
Adolesc Psychopharmacol. 2006;16(4):416–431.
60. Teuscher NS, Sikes CR, McMahen R, et al. Population
pharmacokinetic-pharmacodynamic modeling of a novel methyl-
phenidate extended-release orally disintegrating tablet in pediatric
patients with attention-deficit/hyperactivity disorder. J Clin
Psychopharmacol. 2018 Oct;38(5):467–474.
61. Preskorn SH, Weller EB, Weller RA, et al. Plasma levels of imipra-
mine and adverse effects in children. Am J Psychiatry. 1983;140
(10):1332–1335.
62. Puig-Antich J, Perel JM, Lupatkin W. Plasma levels of imipramine
(IMI) and desmethylimipramine (DMI) and clinical response in pre-
pubertal major depressive disorder. A preliminary report. J Am
Acad Child Psychiatry. 1979;18(4):616–627.
63. Puig-Antich J, Perel JM, Lupatkin W. Imipramine in prepubertal
major depressive disorders. Arch Gen Psychiatry. 1987;44(1):81–89.
64. Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response
to atomoxetine in children and adolescents with ADHD. J Am Acad
Child Adolesc Psychiatry. 2007 Feb;46(2):242–251.
65. Reinblatt SP, Dosreis S, Walkup JT, et al. Activation adverse events
induced by the selective serotonin reuptake inhibitor fluvoxamine
in children and adolescents. J Child Adolesc Psychopharmacol.
2009;19(2):119–126.
66. Taurines R, Burger R, Wewetzer C, et al. The relation between
dosage, serum concentrations, and clinical outcome in children
and adolescents treated with sertraline: A naturalistic study. Ther
Drug Monit. 2013;35(1):84–91.
67. Dugas M, Zarifian E, Leheuzey MF. Preliminary observations of the
significance of monitoring tricyclic antidepressant plasma levels in
the pediatric patient. Ther Drug Monit. 1980;2(4):307–314.
68. Morselli PL, Bianchetti G, Durand G. Haloperidol plasma level mon-
itoring in pediatric patients. Ther Drug Monit. 1979;1(1):35–46.
69. Alfaro CL, Wudarsky M, Nicolson R, et al. Correlation of antipsycho-
tic and prolactin concentrations in children and adolescents
acutely treated with haloperidol, clozapine, or olanzapine. J Child
Adolesc Psychopharmacol. 2002;12(2):83–91.
70. Migliardi G, Spina E, D’Arrigo C, et al. Short- and long-term effects
on prolactin of risperidone and olanzapine treatments in children
and adolescents. Prog Neuro-Psychopharmacol Biol Psychiatry.
2009;33(8):1496–1501.
71. Duval F, Guillon MS, Mokrani MC, et al. Relationship between pro-
lactin secretion, and plasma risperidone and 9-hydroxyrisperidone
concentrations in adolescents with schizophreniform disorder.
Psychoneuroendocrinology. 2008;33(2):255–259.
72. Ngamsamut N, Hongkaew Y, Vanwong N, et al. 9-hydroxyrisperi-
done-induced hyperprolactinaemia in Thai children and adoles-
cents with autism spectrum disorder. Basic Clin Pharmacol
Toxicol. 2016;119(3):267-272.
73. Roke Y, Buitelaar JK, Boot AM, et al. Risk of hyperprolactinemia and
sexual side effects in males 10–20 years old diagnosed with autism
spectrum disorders or disruptive behavior disorder and treated
with risperidone. J Child Adolesc Psychopharmacol. 2012;22
(6):432–439.
74. Troost PW, Lahuis BE, Hermans MH, et al. Prolactin release in
children treated with risperidone: impact and role of CYP2D6
metabolism. J Clin Psychopharmacol. 2007 Feb;27(1):52–57.
75. Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of
childhood-onset schizophrenia: evaluation of effectiveness, adverse
effects, and long-term outcome. J Am Acad Child Adolesc
Psychiatry. 2007;46(10):1349–1356.
76. Frazier JA, Cohen LG, Jacobsen L, et al. Clozapine pharmacokinetics
in children and adolescents with childhood-onset schizophrenia.
J Clin Psychopharmacol. 2003 Feb;23(1):87–91.
77. Wohkittel C, Gerlach M, Taurines R, et al. Relationship between
clozapine dose, serum concentration, and clinical outcome in chil-
dren and adolescents in clinical practice. J Neural Transm. 2016;123
(8):1021–1031.
78. Greenhill LL, Perel JM, Rudolph G, et al. Correlations between
motor persistence and plasma levels in methylphenidate-treated
boys with ADHD. Int J Neuropsychopharmacol. 2001;4(2):207–215.
79. Fekete S, Wewetzer C, Mehler-Wex C, et al. Therapeutic drug
monitoring in children and adolescents under pharmacotherapy
with olanzapine in daily clinical practice. Ther Drug Monit. 2017;39
(3):273–281.
80. Klampfl K, Taurines R, Preuss A, et al. Serum concentrations, ther-
apeutic response and side effects in children and adolescents with
impulsive-aggressive symptoms during risperidone therapy.
Pharmacopsychiatry. 2010;43(2):58–65.
81. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical
effectiveness of methylphenidate. Clin Pharmacokinet. 1999;37
(6):457–470.
82. Ambrosini PJ, Bianchi MD, Metz C, et al. Evaluating clinical response
of open nortriptyline pharmacotherapy in adolescent major
depression. J Child Adolesc Psychopharmacol. 1994;4(4):233–244.
83. Wilens TE, Biederman J, Spencer T, et al. A retrospective study of
serum levels and electrocardiographic effects of nortriptyline in
children and adolescents. J Am Acad Child Adolesc Psychiatry.
1993;32(2):270–277.
84. Soldin OP, Soldin SJ. Review: therapeutic drug monitoring in
pediatrics. Ther Drug Monit. 2002 Feb;24(1):1–8.
85. Gualtieri CT, Hicks RE, Patrick K. Clinical correlates of methylpheni-
date blood levels. Ther Drug Monit. 1984;6(4):379–392.
86. Markowitz JS, Straughn AB, Patrick KS. Advances in the pharma-
cotherapy of attention-deficit-hyperactivity disorder: focus on
methylphenidate formulations. Pharmacotherapy. 2003 Oct;23
(10):1281–1299.
87. Vitiello B, Correll C, van Zwieten-boot B, et al. Antipsychotics in
children and adolescents: increasing use, evidence for efficacy and
safety concerns. Eur Neuropsychopharmacol. 2009 Sep;19
(9):629–635.
88. Gerlach M, Hünnerkopf R, Rothenhöfer S, et al. Therapeutic drug
monitoring of quetiapine in adolescents with psychotic disorders.
Pharmacopsychiatry. 2007;40(2):72–76.
89. Dos Santos-Junior A, Tamascia ML, Lorenzetti R, et al. Serum con-
centration of risperidone and adverse effects in children and
adolescents. J Child Adolesc Psychopharmacol. 2017 Mar;27
(2):211–212.
16 S. M. KLOOSTERBOER ET AL.
90. Hoekstra PJ, Troost PW, Lahuis BE, et al. Risperidone-induced
weight gain in referred children with autism spectrum disorders
is associated with a common polymorphism in the
5-hydroxytryptamine 2C receptor gene. J Child Adolesc
Psychopharmacol. 2010 Dec;20(6):473–477.
91. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and
tolerability of two dosing regimens in adolescent schizophre-
nia: double-blind study. Br J Psychiatry. 2009 Feb;194
(2):158–164.
92. NICE National Institute for Health and Care Excellence. Bipolar
disorder: assessment and management. 2014 [cited 2020 Feb 11].
https://www.nice.org.uk/guidance/cg185
93. Hiemke C. Concentration-effect relationships of psychoactive drugs
and the problem to calculate therapeutic reference ranges. Ther
Drug Monit. 2019 Apr;41(2):174–179.
94. National trends in child and adolescent psychotropic polyphar-
macy in office-based practice, 1996–2007. 2010 Oct.
95. VanderZwaag C, McGee M, McEvoy JP, et al. Response of
patients with treatment-refractory schizophrenia to clozapine
within three serum level ranges. Am J Psychiatry. 1996 Dec;153
(12):1579–1584.
96. Bliznak L, Berg R, Hage A, et al. High rate of non-eligibility: meth-
odological factors impacting on recruitment for a multicentre,
double-blind study of paediatric patients with major depressive
disorder. Pharmacopsychiatry. 2013 Jan;46(1):23–28.
97. Fekete S, Hiemke C, Gerlach M. Dose-related concentrations of neuro-/
psychoactive drugs expected in blood of children and adolescents.
Ther Drug Monit. 2019 Aug 5. DOI: 10.1097/FTD.0000000000000685.
• Provides pharmacokinetic reference values of psychotropic
drugs in children and adolescents.
EXPERT OPINION ON DRUG SAFETY 17
